Grifols

Grifols
Share
Founded in 1940, Grifols is comprised of several companies serving healthcare professionals and patients in over 90 countries. “Working for Health,” Grifols researches, develops, manufactures, and markets high-quality plasma derivatives, IV solutions, enteral nutrition, in vitro laboratory diagnostic products, and a wide range of nonbiological hospital products worldwide.

Grifols

 •  July 9

09.07.2017 Created in 2008, the SPIN Award Program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology The SPIN 2017 was awarded to Ruth Huizinga, PhD from Erasmus Medical Center Rotterdam, to study the effect of IVIg on the B-cell receptor repertoire of patients with the...

Grifols

 •  August 16, 2016

Grifols is proud to support the Canadian Blood Services' Missing Type Campaign. This is a global campaign whose goal is to increase the number of new registered blood donors. In the last decade there has been a downward trend of new registered blood donors, which may put the blood supply at-risk. The Missing Type campaign has asked global brands,...

Grifols

 •  July 28, 2016

Strong positive growth for the four main plasma proteins, that jointly with the others, take the revenues of the Bioscience Division to EUR 1,559.3 million with an increase of +7.0% (+6.7% cc1)
Significant strengthening of the respiratory franchise, with a record number of patients diagnosed with alpha-1 antitrypsin deficiency (AATD) and...

Grifols

 •  July 26, 2016

The 2016 World Congress of the World Federation of Hemophilia took place in Orlando, Florida from 24 to 28 July 2016. After many years, the World Congress returned to US soil; and a turnout of about 8000 people has been registered.
As World Congress Supporter, Kedrion Biopharma was present with a booth and with a large delegation of international...

Grifols

 •  June 30, 2016

Created in 2007, the awards recognize the progress made in the field of Hemostasis. The awards are endowed with 20,000 euros for each of the two prizes: Basic Research and Clinical Research.
The Basic Research category was awarded to Dr. Nimesh Gupta for presenting the antigen-specific tolerance in the administration of missing antigens during...

Grifols

 •  June 22, 2016

Created in 2008, the SPIN Awards Program supports the development and testing of innovative ideas and hypotheses in the field of immunoglobulin research in neurology
The SPIN 2016 was awarded to Luis Querol to support his research project "IVIg effects on regulatory B cells in patients with neuroimmune diseases"
For the eighth consecutive year,...

Grifols

 •  May 7, 2016

GammaSTAN®, Gamunex® / Gamunex-C®, HyperHEP B®, HyperRAB®, HyperRHO®, HyperTET®, Koāte® DVI, Plasbumin®, Prolastin® / Prolastin® C and Thrombate® III are the newly added products.
Grifols has been offering this unique service for free to health professionals for 20 years which provides, in a simple manner, the total traceability of the final...

Grifols

 •  April 18, 2016

Grifols has donated 150,000 euros to support the Foundation's research effort, designed to improve the quality of life of people with intellectual disability One of the lines of research, in partnership with the Hospital de la Santa Creu i Sant Pau, in Barcelona, focuses on the early diagnosis of Alzheimer's disease, which has a much higher...

Grifols

 •  March 8, 2016

Grifols' Board of Directors approves a plan for new industrial investments for the Bioscience Division to ensure the company's long-term sustained growth
With these new investments, Grifols increases its production capacity to continue covering the expected growing demand in the plasma-derived products until 2028-2030
The plan includes the...

Grifols

 •  January 26, 2016

AlbaJuna Therapeutics, a spin-off from the IrsiCaixa AIDS Research Institute, is developing a new treatment strategy based on monoclonal antibodies with great potential to neutralize HIV and activate the "natural killer" cells responsible for destroying cells infected by the virus.The three candidate molecules available have demonstrated in vitro...